Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Skyrizi (risankizumab-rzaa) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorization: 12 months

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Skyrizi (risankizumab-rzaa) .** Please complete and fax this form back to Kaiser Permanente within 24 hours [fax: 1-866-331-2104]. If you have any questions or concerns, please call 1-866-331-2103. **Requests will not be considered unless this form is complete. The KP-MAS Formulary can be found at: http://www.providers.kaiserpermanente.org/mas/formulary.html**

1 – Patient Information

Patient Name: _____ Kaiser Medical ID#: _____ Date of Birth: _____

2 – Provider Information

Provider Name: _____ Specialty: _____ Provider NPI: _____

Provider Address: _____

Provider Phone #: _____Provider Fax #: _____

Please check the boxes that apply:
□ Initial Request □ Continuation of Therapy Request

3 – Pharmacy Information

Pharmacy Name: _____ Pharmacy NPI: _____

Pharmacy Phone #_____ Pharmacy Fax #: _____

4 – Drug Therapy Requested

Drug 1: Name/Strength/Formulation: _____
Sig: _____

Drug 2: Name/Strength/Formulation: _____
Sig: _____

5– Diagnosis/Clinical Criteria

Initial Therapy:

1. Does the member have diagnosis of one of the following? **AND**
   □ Plaque Psoriasis (PsO)
   □ Psoriatic Arthritis (PsA)

□ Other: _____

2. Was there therapeutic failure on oral methotrexate? **AND**
   □ No □ Yes

3. Was there therapeutic failure to one of the preferred agents? (e.g. Enbrel, Humira) **AND**
   □ No □ Yes

4. If this is being used for plaque psoriasis (PSO):
   a. Is the patient ≥ 18 years old? **AND**
      □ No □ Yes

   b. Does the patient have moderate-to-severe plaque psoriasis for at least 6 months? **AND**
      □ No □ Yes

   c. Is there involvement of at least 10% of body surface area (BSA)? **OR**
      □ No □ Yes

   d. Is the Psoriasis Area and Severity Index (PASI) score 10 or greater? **OR**
      □ No □ Yes

   e. Incapacitation due to plaque location (e.g., head and neck, palms, soles or genitalia)? **AND**
      □ No □ Yes

   f. Has the patient not responded adequately (or is not a candidate) to a 3 month minimum trial of topical agents (e.g., anthralin, coal tar preparations, corticosteroids, emollients, immunosuppressives, keratolytics, retinoic acid derivatives, and/or Vitamin D analogues)? **AND**
      □ No □ Yes

   g. Has the patient not responded adequately (or is not a candidate) to a 3 month minimum trial of at least 1 systemic agent (e.g. Immunosuppressives, retinoic acid derivatives, and/or methotrexate)? **AND**
      □ No □ Yes

   h. Has the patient not responded adequately (or is not a candidate) to a 3 month minimum trial of phototherapy (e.g. Psoralens with UVA light (PUVA) OR UVB with coal tar or dithranol)? **AND**
      □ No □ Yes

   i. Is the patient not receiving risankizumab-rzaa in combination with another biologic agent for psoriasis or non-biologic immunomodulator (e.g., apremilast, tofacitinib, baricitinib)?
      □ No □ Yes

6 – Provider Sign-Off

Additional Information – Please provide any additional information that should be taken into consideration.

_____

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Provider Signature:	**Date:**